Inovio Reports INO-3107 Remains on Track for October FDA Decision
Inovio's Q2 2026 presentation indicates that regulatory review for INO-3107 is proceeding as scheduled.
PA
Priya Anand · Equities & Earnings Desk · 16 Aug 2026 · 1 min read
Inovio Pharmaceuticals has confirmed in its second-quarter 2026 presentation materials that its lead candidate, INO-3107, remains on track for a regulatory decision by the U.S. Food and Drug Administration in October.
The update highlights the ongoing development timeline for the therapy as it approaches the scheduled review date.
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →